LIL-HM4A1-100μg / 询价
LIL-HM4A1-500μg / 询价
LIL-HM4A1-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Human LILRA1/CD85i/LIR-6 Protein
Recombinant Human LILRA1/CD85i/LIR-6 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Pro17-Asn461 [Accession | O75019-1].
The protein has a predicted MW of 51.4 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human LILRA1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human LILRA1 is greater than 95% as determined by SEC-HPLC.
LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.
CD85i; LILRA1; LIR6; LIR-6; LIR6MGC126563
(1)The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy[J]. Scandinavian Journal of Immunology, 2019.
